Regulatory Novo Nordisk preps filings for sickle cell drug etavopivat PharmaphorumNovo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.RegulatoryHematologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease. RegulatoryHematologyRead full story Post navigation Previous: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new dataNext: Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
